Clinical trial
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and…
NCT00440765 · Janssen-Cilag B.V., Industry · Completed
Key facts
| NCT number | NCT00440765 |
|---|---|
| Title | VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands |
| Official title | A Post Authorization Study, Designed to Learn More About the Safety and Efficacy of the Use of VELCADE (Bortezomib) in the Netherlands |
| Lead sponsor | Janssen-Cilag B.V., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Multiple Myeloma, Hematological Neoplasms |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 331 |
| Start date | Nov 1, 2004 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Feb 27, 2007 |
| Last update posted | Jan 14, 2014 |
| Countries | Netherlands |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: